November 19, 2020
We're Thankful for You As many celebrate Thanksgiving next week, we wanted to take a moment to extend our sincerest thanks for the continued hard work and outstanding efforts of our cancer research community. Whether you're an investigator, physician, nurse, clinical research professional, pharmacist, pathologist, radiologist, urologist, surgeon, patient advocate, study participant, caregiver, administrator, community site,
November 2, 2020
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide vs. temozolomide and olaparib for advanced pheochromocytoma and paraganglioma
Overview: Alliance investigators Jaydira Del Rivero, of the National Cancer Institute, and Kimberly J. Perez, MD, of the Dana-Farber Cancer Institute, lead this phase II trial that studies how well the addition of olaparib
October 30, 2020
Alliance A071702: A phase II study of checkpoint blockade immunotherapy in patients with somatically hypermutated recurrent glioblastoma
Overview: Alliance investigator Gavin P Dunn, MD, PhD, of Washington University School of Medicine in St. Louis, leads this phase II trial that studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with gliobla
